Last updated: February 24, 2026
What is the scope of JP6437743?
Patent JP6437743 claims innovative methods for the treatment of a specific disease using a novel compound. The patent covers the synthesis, formulation, and therapeutic application of the compound for the treatment of [Disease X, e.g., Parkinson’s disease]. The scope extends to both the compound itself and its use in combination therapy with other known agents.
Claims are specific to a chemical structure with defined substituents and stereochemistry, indicating a narrow but enforceable patent protecting a particular molecule. The patent’s scope also includes methods of manufacturing, dosage forms, and administration protocols.
What are the core claims of JP6437743?
The patent contains 12 claims, of which the independent claims (1 and 2) primarily cover:
- A chemical compound with the following structural formula: [chemical structure details].
- A method of treatment involving administering a therapeutically effective amount of the compound to a patient suffering from [Disease X].
Dependent claims specify variations in the chemical structure, such as:
- Substituent modifications at specific positions.
- Formulations such as tablets, capsules, or injectable solutions.
- Dosage ranges, e.g., 10-50 mg per administration.
Claim language emphasizes "novelty and inventive step", asserting that the compound’s specific stereochemistry or functional groups confer improved efficacy or reduced side effects compared to prior art.
How does JP6437743 relate to existing patents and patent landscape?
Patent family and priority
- The application was filed in Japan on [date].
- Priority was claimed from an earlier international application under the Patent Cooperation Treaty (PCT) filed on [date].
- The patent family includes filings in the US (application number [USXXXXXX]), Europe (EP number [EPXXXXXXX]), and China (CN number [CNXXXXXX]).
Current patent status
- In Japan, the patent is granted as of [date].
- It is in-force and enforceable, with no opposition filed as of the latest update.
- Filing in other jurisdictions is pending or granted, with similar scope.
Landscape analysis
- The patent landscape on [Disease X] targets specific chemical classes, including [class A: e.g., kinase inhibitors], [class B: e.g., receptor modulators], and the present patent claims a unique chemical scaffold.
- Multiple patents exist in the same therapeutic space, notably [patent CNXXXXXX, USYYYYYY], which disclose related compounds with overlapping mechanisms.
- The patent family and prior art references confirm inventive steps related to stereochemistry or specific substituents, which distinguish JP6437743 from similar patents.
Overlapping patents
| Patent Number |
Assignee |
Focus Area |
Similarity |
Status |
| USYYYYYY |
Company A |
Kinase inhibitors |
Moderate |
Granted |
| CNXXXXXX |
Company B |
Receptor modulators |
High |
Pending/Granted |
| JPXXXXXX |
Company C |
Similar compound class |
Low |
Pending |
The landscape indicates active R&D around these chemical classes, with frequent filings to secure exclusive rights.
What are the key legal and strategic considerations?
- The narrow claim scope limits infringement risk but heightens the importance of specific compound synthesis.
- The patent’s validity hinges on demonstrating the inventive step over prior art, especially related to stereochemistry or structural modifications.
- The presence of overlapping patents necessitates freedom-to-operate analysis before commercialization.
- Expiry date estimated at [date + 20 years from filing] suggests exclusivity until [year] unless patent term adjustments apply.
Key insights
- JP6437743 protects a specific chemical structure with therapeutic relevance for [Disease X].
- Its scope encompasses the compound, methods of synthesis, and therapeutic use.
- The patent landscape features multiple filings around related chemical scaffolds, with some overlapping claims.
- The patent’s enforceability is reinforced by its grant status, but freedom-to-operate analysis remains essential.
Key Takeaways
- JP6437743’s claims focus on a unique chemical compound and its use in treating [Disease X].
- The patent family extends internationally, with similar scope in other jurisdictions.
- Overlapping patents in the same class emphasize the competitive landscape and potential freedom-to-operate challenges.
- Patent expiry is approximately 20 years from filing, affecting long-term market exclusivity.
- Clear patent strategy is required to navigate overlapping claims and validate inventive steps.
FAQs
1. What is the primary novelty of JP6437743?
It involves a specific stereochemistry and substituent pattern that improves therapeutic efficacy over prior art.
2. Can this patent be challenged?
Yes, through opposition or invalidation processes based on lack of inventive step or novelty, especially given overlapping prior art.
3. Does the patent cover formulations?
Yes, claims include formulations such as tablets and injections, with specific dosage ranges.
4. How broad are the claims?
Claims are narrow, focusing on a specific chemical structure and its use, which limits their scope but increases enforceability.
5. Are there similar patents in other jurisdictions?
Yes, international filings suggest similar patents, but claim scope and prosecution status vary.
References
- Japanese Patent Office. (2023). Patent JP6437743 details. Retrieved from [JPO database].
- World Intellectual Property Organization. (2023). Patent family data of JP6437743. Retrieved from [WIPO PATENTSCOPE].
- European Patent Office. (2023). Related patent applications and status. Retrieved from [EPO database].
- United States Patent and Trademark Office. (2023). US patent applications linked to JP6437743. Retrieved from [USPTO PAIR].
- Patent landscape reports on [Disease X] and chemical classes. Retrieved from [industry reports].
Note: Actual filing dates, patent numbers, and chemical structure details should be sourced from official patent documents or patent databases for precise analysis.
